Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

NCT ID: NCT02134210

Last Updated: 2019-06-28

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

521 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-16

Study Completion Date

2016-05-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a two part study comparing CHS-0214 to Enbrel in patients with chronic plaque PsO who have not yet received any biologic therapy for any indication (other than insulin or hormones).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pt. 1 is a 12-week randomized, double-blind, active-control, parallel-group, multi-center global study. The primary end point is 75% improvement from baseline according to the Psoriasis Area and Severity Index (PASI-75). Comparing CHS-0214 to Enbrel for efficacy and safety at a dosage of 50mg subcutaneous (Sc) twice weekly.

Pt. 2 is a 40-week randomized, double-blind, active-control, parallel-group, multi-center global study where CHS-0214 and Enbrel dosage is reduced to 50mg Sc weekly for maintenance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plaque Psoriasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Enbrel (etanercept)

Enbrel 50mg twice weekly times 12 weeks

Group Type ACTIVE_COMPARATOR

Etanercept

Intervention Type DRUG

Head-to-head comparison

CHS-0214

CHS-0214 50mg twice weekly times 12 weeks

Group Type EXPERIMENTAL

CHS-0214

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Etanercept

Head-to-head comparison

Intervention Type DRUG

CHS-0214

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Enbrel European Enbrel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female adults
* PsO diagnosis for 6 months
* Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment (PSGA) score greater than or equal to 3 (based on a scale or 0-5),
* Body Surface Area (BSA) involved with PsO greater than or equal to 10%
* Dermatology Life Quality Index (DQLI) greater than or equal to 10
* Previously received phototherapy or systemic non-biologic therapy for PsO

Exclusion Criteria

* Forms of Psoriasis other than PsO
* Drug induced Psoriasis
* Positive QuantiFERON-tuberculosis (TB) Gold Test
* Presence of significant comorbid conditions
* Chemistry and hematology values outside protocol specified range
* Major systemic infections
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shire

INDUSTRY

Sponsor Role collaborator

Coherus Oncology, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Barbara K Finck, M.D.

Role: STUDY_DIRECTOR

Coherus Oncology, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arizona Research Center

Phoenix, Arizona, United States

Site Status

Radiant Research - Scottsdale

Scottsdale, Arizona, United States

Site Status

Anaheim Clinical Trials

Anaheim, California, United States

Site Status

Dream Team Clinical Research

Anaheim, California, United States

Site Status

Private Practice

Encino, California, United States

Site Status

Kaiser Permanente

Los Angeles, California, United States

Site Status

Skin Surgery Medical Group, Inc

San Diego, California, United States

Site Status

Clinical Science Institute

Santa Monica, California, United States

Site Status

Healthcare Partners Medical Group

Torrance, California, United States

Site Status

Horizons Clinical Research Center

Denver, Colorado, United States

Site Status

The Savin Center

New Haven, Connecticut, United States

Site Status

New England Research Associates

Trumbull, Connecticut, United States

Site Status

Florida Academic Dermatology Center (U of Miami Hospital)

Miami, Florida, United States

Site Status

Radiant Research - Pinellas Park

Pinellas Park, Florida, United States

Site Status

Atlantic Clinical Research Collaborative

West Palm Beach, Florida, United States

Site Status

Palm Beach Research Center

West Palm Beach, Florida, United States

Site Status

Radiant Research - Atlanta

Atlanta, Georgia, United States

Site Status

Private Practice - Jamie Weisman

Atlanta, Georgia, United States

Site Status

Altman Dermatology Associates

Arlington Heights, Illinois, United States

Site Status

Springfield Clinic

Springfield, Illinois, United States

Site Status

The Indiana Clinical Trials Center

Plainfield, Indiana, United States

Site Status

Kansas City Dermatology

Overland Park, Kansas, United States

Site Status

Derm Research

Louisville, Kentucky, United States

Site Status

Hamzavi Dermatology Clinical Research

Fort Gratiot, Michigan, United States

Site Status

Grekin Skin Institute

Warren, Michigan, United States

Site Status

Radiant Research - Edina

Edina, Minnesota, United States

Site Status

Central Dermatology

St Louis, Missouri, United States

Site Status

The Psoriasis Treatment Center of Central New Jersey

East Windsor, New Jersey, United States

Site Status

Skin Search of Rochester, Inc

Rochester, New York, United States

Site Status

DermResearch Center of New York

Stony Brook, New York, United States

Site Status

PMG Research of Carey, LLC

Cary, North Carolina, United States

Site Status

DJL Clinical Research

Charlotte, North Carolina, United States

Site Status

PMG Research of Wilmington

Wilmington, North Carolina, United States

Site Status

Radiant Research

Cincinnati, Ohio, United States

Site Status

Health Research of Oklahoma

Oklahoma City, Oklahoma, United States

Site Status

Altoona Center for Clincal Research

Duncansville, Pennsylvania, United States

Site Status

Clinical Research Center of Reading

Wyomissing, Pennsylvania, United States

Site Status

Radiant Research - Anderson

Anderson, South Carolina, United States

Site Status

Dermatology and Laser Center of Charleston

Charleston, South Carolina, United States

Site Status

Radient Research - Greer

Greer, South Carolina, United States

Site Status

Rivergate Dermatology

Goodlettsville, Tennessee, United States

Site Status

Neighborhood Medical Center

Dallas, Texas, United States

Site Status

Center for Clinical Studies

Houston, Texas, United States

Site Status

Heights Dermatology and Aesthetic Center

Houston, Texas, United States

Site Status

Progressive Clinical Research - San Antonio

San Antonio, Texas, United States

Site Status

Center for Clinical Studies

Webster, Texas, United States

Site Status

Dermatology Associates, PLLC

Seattle, Washington, United States

Site Status

Premier Clinical Research

Spokane, Washington, United States

Site Status

Wenatchee Valley Hospital and Clinics

Wenatchee, Washington, United States

Site Status

Mountain State Clinical Research

Clarksburg, West Virginia, United States

Site Status

Woden Dermatology Pty

Phillip, Australian Capital Territory, Australia

Site Status

Dr S P Shumack (St George Dermatology and Skin Cancer Center)

Kogarah, New South Wales, Australia

Site Status

Dr S P Shumack (Central Sydney Dermatology)

Sydney, New South Wales, Australia

Site Status

North Eastern Health Specialists

Hectorville, South Australia, Australia

Site Status

Sinclair Dermatology

East Melbourne, Victoria, Australia

Site Status

E and D Woolner Professional Corporation

Calgary, Alberta, Canada

Site Status

Institute for Skin Advancement Inc

Calgary, Alberta, Canada

Site Status

CCA Medical Research Corporation

Ajax, Ontario, Canada

Site Status

Lynderm Research Inc

Markham, Ontario, Canada

Site Status

North Bay Dermatology Centre Inc

North Bay, Ontario, Canada

Site Status

Institute of Cosmetic and Laser Surgery

Oakville, Ontario, Canada

Site Status

SKiN Center for Dermatology

Peterborough, Ontario, Canada

Site Status

Private Practice

Richmond Hill, Ontario, Canada

Site Status

Research Toronto

Toronto, Ontario, Canada

Site Status

K. Papp Clinical Research Inc

Waterloo, Ontario, Canada

Site Status

MVZ Reichenberger Str., Aerztehaus "Rudolf Virchow

Berlin, , Germany

Site Status

Klinische Forschung Dresden GmbH

Dresden, , Germany

Site Status

Hautklinik Universitaetsklinikum Erlangen

Erlangen, , Germany

Site Status

Johann Wolfgang Hospital - Goethe University

Frankfurt, , Germany

Site Status

Dermatologikum Hamburg

Hamburg, , Germany

Site Status

University Hospital Schleswig-Holstein - Campus Luebeck

Lübeck, , Germany

Site Status

Haemek Medical Center

Afula, , Israel

Site Status

Rambam Health Care Campus

Haifa, , Israel

Site Status

Rabin Medical Center Beilinson Campus

Petah Tikva, , Israel

Site Status

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik

Bialystok, , Poland

Site Status

Niepubliczny Zaklad Opieki Zdrowotnej Centrum Osteoporozy i Chorób Kostno-Stawowych J. Badurski S.J

Bialystok, , Poland

Site Status

Centrum Badan Klinicznych PI-House Sp. Z o.o

Gdansk, , Poland

Site Status

Synexus Polska Sp. z o.o. Oddzial w Gdyni

Gdynia, , Poland

Site Status

Synexus Polska Sp. z o.o. Oddzial w Katowicach

Katowice, , Poland

Site Status

Specjalistyczny Osrodek ALL-MED

Krakow, , Poland

Site Status

Krakowskie Centrum Medyczne

Krakow, , Poland

Site Status

Center Med

Krakow, , Poland

Site Status

Specjalistyczne Gabinety Lekarskie "Dermed

Lodz, , Poland

Site Status

Centrum Medyczne SYNEXUS POZNAN

Poznan, , Poland

Site Status

Centrum Medyczne Medyk

Rzeszów, , Poland

Site Status

SANUS Szpital Specjalistyczny Sp. z o.o

Stalowa Wola, , Poland

Site Status

EuroMedis Sp. z o.o.

Szczecin, , Poland

Site Status

NZOZ "Nasz Lekarz" Praktyka Grupowa Lekarzy z Przychodnia Specjalistyczna

Torun, , Poland

Site Status

Synexus Polska Sp. z o.o. Oddzial w Warszawie

Warsaw, , Poland

Site Status

MTZ Clinical Research Sp. z o.o.

Warsaw, , Poland

Site Status

Synexus Polska sp. z o.o

Wroclaw, , Poland

Site Status

Dermmedica Sp. z o.o

Wroclaw, , Poland

Site Status

Vincent Pallotti Hospital

Pinelands, Cape Town, South Africa

Site Status

Synopsis Research

Rondebosch, Cape Town, South Africa

Site Status

Jongaie Research

Pretoria West, Pretoria, South Africa

Site Status

Helderberg Clinical Trial Centre

Somerset West, Western Cape, South Africa

Site Status

Dr IC Louw

Cape Town, , South Africa

Site Status

Winelands Rheumatology Centre

Stellenbosch, , South Africa

Site Status

Clinical Projects Research

Worcester, , South Africa

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada Germany Israel Poland South Africa

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHS-0214-04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Mechanism of Action Study for Psoriasis
NCT00932113 COMPLETED PHASE4